Brooks Laboratories
Brooks Laboratories Share Price Chart
Brooks Laboratories last traded at ₹65.21 (2026-10-13). Over the past month the stock moved +2.9%, three months the stock moved +9.3%, year the stock moved -55.9%. Its closing range over 52 weeks is ₹43.28 – ₹123.65, with the latest close 47.3% below the high.
Closing prices up to 2026-10-13.
About Brooks Laboratories
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]
Business Overview:[1] BLL is an EU GMP & ISO 9001:2008 certified manufacturer and marketer of pharmaceutical formulations
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Brooks Laboratories reported sales of ₹22.96 crore (-10.0%) and net profit of ₹-1.79 crore (-118.7%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 22.96 | -1.34 | -5.84 | -1.79 | -0.61 |
| Mar 2026 | 20.21 | 0.68 | 3.36 | 1.52 | 0.52 |
| Dec 2025 | 16.57 | 0.73 | 4.41 | 5.50 | 1.87 |
| Sep 2025 | 23.45 | 2.52 | 10.75 | 7.98 | 2.71 |
| Jun 2025 | 25.51 | 3.13 | 12.27 | 9.58 | 3.25 |
| Mar 2025 | 23.32 | -1.26 | -5.40 | -1.46 | -0.50 |
| Dec 2024 | 20.52 | -1.50 | -7.31 | -2.13 | -0.81 |
| Sep 2024 | 20.79 | -3.41 | -16.40 | -3.96 | -1.51 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -14.5% | -5.7% | +31.6% | +42.3% | +12.8% | -19.2% | -13.3% | -10.0% |
| Operating profit growth | – | – | – | – | – | – | – | -142.8% |
| Net profit growth | – | – | – | – | – | – | – | -118.7% |
| EPS growth | – | – | – | – | – | – | – | -118.8% |
| OPM % | -16.4% | -7.3% | -5.4% | 12.3% | 10.8% | 4.4% | 3.4% | -5.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Brooks Laboratories reported sales of ₹86.00 crore (+4.2%) and net profit of ₹25.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 86.00 | 7.00 | 8.00 | 25.00 | 8.34 |
| Mar 2025 | 82.56 | -8.04 | -9.74 | -9.97 | -3.38 |
| Mar 2024 | 79.49 | -17.91 | -22.53 | -19.59 | -7.46 |
| Mar 2023 | 63.20 | -29.73 | -47.04 | -31.04 | -7.97 |
| Mar 2022 | 91.18 | -14.25 | -15.63 | -19.31 | -4.31 |
| Mar 2021 | 77.25 | 0.57 | 0.74 | -19.38 | -7.40 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales growth | +18.0% | -30.7% | +25.8% | +3.9% | +4.2% |
| Operating profit growth | -2600.0% | – | – | – | – |
| Net profit growth | – | – | – | – | – |
| EPS growth | – | – | – | – | – |
| OPM % | -15.6% | -47.0% | -22.5% | -9.7% | 8.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Brooks Laboratories.
Get Free AI Stock Analysis FREE →Latest News
-
Brooks Laboratories incorporates wholly owned subsidiary Abridge Speciality - scanx.trade
Frequently Asked Questions
What is the share price of Brooks Laboratories today?
Brooks Laboratories shares were last quoted at ₹65.21 (-7.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Brooks Laboratories?
Brooks Laboratories has a price-to-earnings (P/E) ratio of 13.13 and a price-to-book (P/B) ratio of 1.40. The industry P/E is 53.33.
What is the 52-week high and low of Brooks Laboratories?
The 52-week high of Brooks Laboratories is ₹143.60 and the 52-week low is ₹36.90.
What is the market cap of Brooks Laboratories?
The market capitalisation of Brooks Laboratories is about ₹173.68 crore.
How did Brooks Laboratories perform in its latest quarterly results?
In the latest quarter (Jun 2026), Brooks Laboratories reported sales of ₹22.96 crore (-10.0%) and net profit of ₹-1.79 crore (-118.7%), compared with the same quarter last year.
Is Brooks Laboratories a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Brooks Laboratories has a 3-year ROE of -2.00%, 3-year profit growth of 47.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Brooks Laboratories?
Promoters hold about 52.62% of Brooks Laboratories.
Which sector does Brooks Laboratories belong to?
Brooks Laboratories belongs to the Pharmaceuticals & Drugs sector.